Publications by authors named "Yuki Habu"

Article Synopsis
  • No effective therapeutic drugs are available for nonalcoholic steatohepatitis (NASH), a liver condition that progresses from nonalcoholic fatty liver; PPAR subtypes (α, δ, γ) are potential targets for treatment.
  • Current clinical trials are examining lanifibranor (a pan agonist) and saroglitazar (a dual agonist), while the development of other dual/pan agonists like seladelpar and elafibranor has been halted due to side effects or lack of efficacy.
  • The study evaluated the binding and activation of lanifibranor, seladelpar, and elafibranor on PPARs using several assays and high-resolution cocrystal
View Article and Find Full Text PDF

Beige adipocytes are transiently induced during early postnatal period in mice. Previous studies have suggested that, unlike in adults, the induction is independent of the sympathetic nerve activity; however, the mechanism is yet unknown. Here, we showed that beige adipocytes are induced during the preweaning period in association with the formation of microbiota in mice.

View Article and Find Full Text PDF

Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists are expected to be the next-generation metabolic disease drug. In addition, some dual/pan PPAR agonists are currently being investigated via clinical trials as one of the first curative drugs against nonalcoholic fatty liver disease (NAFLD). Because PPARα/δ/γ share considerable amino acid identity and three-dimensional structures, especially in ligand-binding domains (LBDs), clinically approved fibrates, such as bezafibrate, fenofibric acid, and pemafibrate, could also act on PPARδ/γ when used as anti-NAFLD drugs.

View Article and Find Full Text PDF